SVB Leerink Rising

Had anyone in healthcare been paying attention to Leerink after they were acquired by SVB. They've recently had new hires from Guggenheim, Bank of America, Goldman, and are continuing to hire quickly. I would think this is a really good sign for the future.

77 Comments
 

Could be more hires coming. Honestly totally agree that they could be a big player pretty soon.

 

from my understanding, leerink does more life sciences like pharma, mRNA mod, imaging etc companies. stuff I'm personally a bit more interested in while MTS is more services and thus gets more M&A. this may change with the new hires tho. sounds like they've built a pretty well diversified new platform with lending, m&a and they're leveraging SVBs balance sheet as well. revenue doubled last year so they're doing really well. previously mts was probably a better platform to get into PE, not sure now.

 

MTS's big year was def 2019 when that ex Lazard guy they got in Japan was helping pull all those Japanese deals. I think they have a pretty good practice out there. Their SPAC picked up Specialists On Call tho so maybe theyll make bank from that.

Dayman?
 

Can someone explain how this will work for SVB? UBS SF had a great point of contact/fee generation via their sponsor business. But without the balance sheet are these guys making bets that they'll get compensated more to cover up for the potential loss of clients they can't provide enough value for via the balance sheet?

 

anonymousmonkey241

Can someone explain how this will work for SVB? UBS SF had a great point of contact/fee generation via their sponsor business. But without the balance sheet are these guys making bets that they'll get compensated more to cover up for the potential loss of clients they can't provide enough value for via the balance sheet?

SVB has balance sheet. Silicon Valley BANK.

 

also incoming. I would think it would mean instead of mostly ECM, were gonna be getting services LBOs/M&A/Lev fin and now software deals (auerbach does big stuff too).

 

Eventually. Balance sheet is still small. Sub $100bn. Hard to be significant TLB or revolver underwriter with that size when compared to the banking giants. The top 2-3 lenders usually have the best insight with the company (there are certainly exceptions). Will certainly be competitive on MM deals but can't really finance many BB deals despite bringing in the UBS team. Of course this is less of an issue for much of tech which often have low leverage unless its PE-backed.

 

interesting for sure. I'm too young to have seen something like this happen. Do you think UBS will carry their strength with them? I saw someone mention they may not have the balance sheet to leverage.

 

do you think there will be more hires coming? Especially since there seems to have been a talent drain among other banks?

 

Only an intern, but I'd think so. They have been on a hiring spree over the past 3 or so months, and now adding UBS's team on the tech side, I'm sure they will have more hires to bolster that team and build it out. Don't see hiring stopping as of yet, but of course at a certain point they are going to hold off for fear of overextension.

 

Personally seems like a very risky time to extend like this. Seems markets have been optimistic so long, things are just now slowing down for downwards.

 

They just hired an MD from Bank of America today I believe in Pharma. Bloomberg released that there was 9 UBS hires total.

 

Kinda sad but I don't think they poached any analysts, associates or directors from the UBS TMT team. I had always heard that when seniors would move to another bank, they would take their favorite analysts / associates / directors with them, but sadly, this wasn't the case. Given they need more people though, I would imagine if any of the top bucket juniors liked working with the seniors, they would be applying for these jobs / getting in contact with the seniors to see if they can move over as well. At the same time, I wouldn't be surprised if most of them are already heavily involved in searching for new opportunities given the UBS TMT team is now very much done for.

 

In regards to their recent hires, they've already been a top player in biopharma for quite some time. They're working on building out their services team and levfin capabilities as they have been somewhat lackluster in that vertical compared to biopharma.

 

Vitae beatae distinctio veniam autem ut in. Perspiciatis illo ut qui vitae.

 

Aliquam asperiores omnis consequatur odit. Dolores consequuntur porro ratione omnis aperiam et labore. Maiores iure veniam omnis consequuntur consectetur aut dolor omnis.

Consequuntur qui officiis molestias. Explicabo eum est vel dicta in eos exercitationem. Accusamus dolorum ipsam rerum assumenda cupiditate. Velit repudiandae voluptatem ipsam laborum hic eum. Quidem et iure rerum atque qui non. At qui accusantium illum sunt voluptatem.

Perspiciatis sint fuga animi quasi sunt deleniti. Molestiae quasi nostrum reprehenderit similique. Voluptatem expedita quis minus quia et esse illo.

 

Sit iste odio sunt qui ut nemo. Ex a sed officia voluptates earum. Sapiente est et a et.

Consequatur velit amet aliquam a ullam vero. Doloremque odio ad veritatis. Sed error a voluptatem. Mollitia autem at sit iusto ea aut est.

Similique ea provident et illum neque optio. Inventore reiciendis molestiae sit esse hic incidunt ullam architecto. Autem rerum magni esse praesentium. Quaerat aspernatur quo natus deleniti ex nostrum sequi.

Illum perspiciatis nostrum consequatur numquam nam doloremque. Quia dolor nesciunt qui rerum ut facere. Est voluptate ut eos ullam sed ullam eligendi. Et omnis adipisci ratione.

Career Advancement Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Goldman Sachs 01 97.9%
  • Morgan Stanley 07 97.3%

Overall Employee Satisfaction

September 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 03 98.9%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 12 97.3%

Professional Growth Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.3%

Total Avg Compensation

September 2026 Investment Banking

  • Vice President (16) $429
  • Associates (53) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (28) $184
  • Intern/Summer Associate (15) $159
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
Secyh62's picture
Secyh62
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
CompBanker's picture
CompBanker
98.9
6
dosk17's picture
dosk17
98.9
7
DrApeman's picture
DrApeman
98.9
8
Betsy Massar's picture
Betsy Massar
98.9
9
GameTheory's picture
GameTheory
98.9
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”